Key points are not available for this paper at this time.
The Ginkgo biloba (G. biloba), commonly known as ginkgo, brings considerable benefit to common medicine, including weight loss effects, as well as antidiabetic, antihypertensive, and antilipidemic properties that could be effective in the treatment of Metabolic syndrome (MetS) associated with increased risk of cardiovascular disease events. Major compounds of G. biloba are terpene lactones (bilobalide and ginkgolides A, B, and C) and flavone glycosides (isorhamnetin, quercetin, and kaempferol). We evaluated the most relevant original articles to indicate the effects of G. biloba on different components of MetS, including obesity, high blood pressure, dyslipidemia, and hyperglycemia. Several electronic databases (Scopus, PubMed, Web of Science and Google Scholar) were searched and the articles that included Ginkgo's effect on one or more of the criteria for MetS were selected. This review indicated that G. biloba might be efficient in the improvement of MetS; however, more studies especially clinical trials are needed to evaluate safety and efficacy of G. biloba.
Eisvand et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: